Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%78 EV-to-EBIT is 7.21 as of Jul. 21, 2026, which is 4% above its 10-year median of 6.95. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 94 Medical Distribution companies, Sinopharm Group Co ranks better than 69.15% on this metric.
Sinopharm Group Co (OTCPK:SHTDF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sinopharm Group Co's Enterprise Value for the quarter that ended in Dec. 2025 was $18,389 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2,405 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co EV-to-EBIT Related Terms
Sinopharm Group Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EV-to-EBIT falls into.
Sinopharm Group Co's current Enterprise Value is $17,347 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2,405 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a EV-to-EBIT of 7.21 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sinopharm Group Co and its competitors. This is near median its historical median of 6.95. Over the past decade, Sinopharm Group Co's EV-to-EBIT has ranged from 4.59 to 12.17. According to the industry distribution chart, Sinopharm Group Co ranks #29 out of 94 companies in the Medical Distribution industry, placing it in the top 30.9%.
Is Sinopharm Group Co's EV-to-EBIT too high?
Sinopharm Group Co's current EV-to-EBIT of 7.21 is near median its 10-year median of 6.95. Over the past 10 years, this metric has ranged from a low of 4.59 to a high of 12.17. The Medical Distribution industry median EV-to-EBIT is 12.03. Sinopharm Group Co's value of 7.21 is 40% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #29 out of 94 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #29 out of 94 companies for EV-to-EBIT. This puts Sinopharm Group Co in the upper half of its industry. The industry median EV-to-EBIT is 12.03. Sinopharm Group Co's value of 7.21 is 40% below this benchmark. Historically, Sinopharm Group Co's own EV-to-EBIT has ranged from 4.59 to 12.17 over the past decade. While the company's 10-year median is 6.95 vs. the industry median of 12.03, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 12.03, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current EV-to-EBIT of 7.21 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 12.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current EV-to-EBIT is 7.21, which is near median its own 10-year median of 6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current EV-to-EBIT is 7.21, which is near median its 10-year median of 6.95 and 40% below the Medical Distribution industry median of 12.03. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current EV-to-EBIT is 7.21 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
EV-to-EBIT: 7.21 (near median its 10-year median of 6.95)
GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
Industry Position: 40% below the Medical Distribution median (#29 of 94)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
